Pacific Biosciences Valuation Multiples

Pacific Biosciences Overview

About Pacific Biosciences

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.

Founded

2000

HQ

Employees

575

Website

pacb.com

Sectors

Diagnostics & GenomicsLife Sciences ToolsBioTechDeepTech

Financials (LTM)

Revenue: $164M

EBITDA: ($146M)

EV

$933M

Valuation Multiples

Multiples.vc

Start free trial

Pacific Biosciences Financials

Pacific Biosciences reported last 12-month revenue of $164M and negative EBITDA of ($146M).

In the same LTM period, Pacific Biosciences generated $54M in gross profit, ($146M) in EBITDA losses, and had net loss of ($430M).

Pacific Biosciences P&L

In the most recent fiscal year, Pacific Biosciences reported revenue of $160M and EBITDA of ($153M).

Pacific Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX

Pacific Biosciences Stock Performance

Pacific Biosciences has current market cap of $510M, and enterprise value of $933M.

Pacific Biosciences' stock price is $1.69.

Pacific Biosciences Valuation Multiples

Pacific Biosciences trades at 5.7x EV/Revenue multiple, and (6.4x) EV/EBITDA.

Pacific Biosciences Financial Valuation Multiples

As of April 19, 2026, Pacific Biosciences has market cap of $510M and EV of $933M.

Equity research analysts estimate Pacific Biosciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Pacific Biosciences has a P/E ratio of (1.2x).

Pacific Biosciences Margins & Growth Rates

Pacific Biosciences' revenue in the last 12 month grew by 10%.

Pacific Biosciences' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $1.0M for the same period.

Pacific Biosciences' rule of 40 is (59%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Pacific Biosciences' rule of X is (45%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Pacific Biosciences Public Comps

See public comps and valuation multiples for other Diagnostics & Genomics and Life Sciences Tools comps.

Pacific Biosciences M&A Activity

Pacific Biosciences acquired XXX companies to date.

Last acquisition by Pacific Biosciences was on XXXXXXXX, XXXXX. Pacific Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Pacific Biosciences Investment Activity

Pacific Biosciences invested in XXX companies to date.

Pacific Biosciences made its latest investment on XXXXXXXX, XXXXX. Pacific Biosciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).